Can I Sell a Term Life Insurance Policy If I Have Cancer?
Yes. Term life insurance policies are the most common policy type processed by Cancer Care Financial — and the answer to this question matters more than almost any other for cancer patients, because most patients with term policies have already been told the opposite. Insurance companies routinely tell policyholders that a term policy has no value because it has no cash surrender value. That answer is accurate as far as it goes, and it is also incomplete. It describes what the insurance company can do. It says nothing about what the secondary market can do. A term life insurance policy held by a cancer patient can be sold through a viatical settlement — often for significant immediate cash — even though the insurance company itself would offer nothing for it. Cancer Care Financial is the nation’s leading viatical settlement broker specializing exclusively in cancer patients and seriously ill individuals, with an average client age of 48 years old and term policies representing the primary source of the transactions we complete.
Why Term Policies Are Treated Differently by Insurance Companies and the Secondary Market
A term life insurance policy is designed to provide coverage for a specific period — 10, 20, or 30 years — in exchange for a fixed or scheduled premium. Unlike whole life or universal life policies, term policies do not build cash value over time. When a policyholder asks their insurance company what the policy is worth, the honest answer from the carrier is usually nothing, because there is no surrender value to pay out.
The secondary market values a policy differently. Institutional buyers who purchase viatical settlements are not interested in surrender value. They are purchasing a financial instrument — the right to receive the death benefit in exchange for taking over the premiums and the risk. For a buyer, a term policy held by a cancer patient can represent significant value, depending on the remaining length of the term, the size of the death benefit, and the patient’s specific diagnosis.
This is the gap that costs patients the most. A patient who only asks their insurance company assumes the answer they receive — nothing — applies everywhere. It does not.
What Determines Whether a Term Policy Can Be Sold
Not every term policy will produce the same result, and Cancer Care Financial believes in setting honest expectations rather than promising outcomes. Several factors determine whether a specific term policy is a strong candidate for a viatical settlement:
Remaining term length. A policy with many years remaining on its term is generally a stronger candidate than one nearing the end of its term, because the buyer is taking on a longer premium obligation in exchange for the eventual death benefit.
Death benefit size. Policies with $100,000 or more in death benefit consistently attract stronger buyer interest. Smaller policies can still qualify, but the pool of interested buyers is often more limited.
Conversion option. Some term policies include a conversion feature that allows them to be converted to a permanent policy. A convertible term policy can be an especially attractive asset in the secondary market, because it gives the buyer additional flexibility.
Diagnosis and staging. As with any viatical settlement, the patient’s specific cancer type and stage are evaluated together with the policy details — not in isolation.
No single factor disqualifies a policy on its own. The only way to know what a specific term policy could produce is to have it evaluated.
A Common Scenario Cancer Care Financial Sees Often
Many cancer patients who carry term life insurance are younger than the population most people associate with life insurance settlements. A patient in their 30s or 40s who purchased a 20-year term policy to protect a young family may be diagnosed with cancer well before that term expires.
In this situation the patient often assumes the policy is simply something to keep paying for, or to let lapse if the premiums become unaffordable. Neither of those is usually the best option. A term policy in this situation — particularly one with a meaningful death benefit and a number of years remaining — can be one of the more competitive policies Cancer Care Financial brings to market, because buyers are weighing a longer time horizon against a specific diagnosis.
What to Do Before Contacting Cancer Care Financial About a Term Policy
Patients who are unsure whether their term policy could qualify do not need to have every detail figured out before reaching out. Having the basic policy documents available — the original policy illustration, the death benefit amount, and the remaining term length — makes the initial evaluation faster, but Cancer Care Financial can begin the conversation with whatever information a patient currently has.
The free Cancer Care Financial calculator at cancercarefinancial.com/viatical-settlement-calculator provides an approximately 90% accurate three-tier estimate using basic policy and diagnosis information, with no contact information required.
Frequently Asked Questions About Selling Term Life Insurance With Cancer
Yes. Term life insurance is the most common policy type processed by Cancer Care Financial. While a term policy has no cash surrender value through the insurance company, it can often be sold for significant cash through a viatical settlement. The secondary market values the policy differently than the insurance company does. Contact Cancer Care Financial at cancercarefinancial.com or 1-844-440-7355 for a free no-obligation evaluation of your specific policy.
That answer is accurate but incomplete. Insurance companies are referring to cash surrender value, which term policies generally do not have. The secondary market evaluates a term policy differently — as a financial instrument with potential value based on the remaining term length, the death benefit amount, and the policyholder's diagnosis. A policy with no surrender value can still produce a meaningful offer through a competitive viatical settlement auction.
Yes, remaining term length is one of several factors that affect a term policy's value in the secondary market. Generally, a policy with more years remaining is viewed favorably by buyers, since it represents a longer window in which the death benefit could be realized. This is evaluated together with the death benefit size and the patient's diagnosis, not in isolation.
A conversion option can make a term policy a more attractive asset to buyers, but its absence does not automatically disqualify a policy. Many term policies without conversion features are still successfully sold through Cancer Care Financial's competitive auction process. The combination of death benefit size, remaining term, and diagnosis determines the outcome more than any single feature.